P Lorenzini
Overview
Explore the profile of P Lorenzini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
225
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fabbri G, Mastrorosa I, Vergori A, Timelli L, Lorenzini P, Zaccarelli M, et al.
HIV Med
. 2018 Jun;
PMID: 29953713
Objectives: Only a few studies have addressed liver stiffness dynamics after hepatitis C virus (HCV) treatment in patients with HIV/HCV coinfection. The aim was to evaluate the variation in liver...
2.
Puoti M, Lorenzini P, Cozzi-Lepri A, Gori A, Mastroianni C, Rizzardini G, et al.
Clin Microbiol Infect
. 2016 Dec;
23(4):267.e1-267.e4.
PMID: 27956268
Objective: To estimate the incidence of hepatitis C virus (HCV) seroconversion and the risk of severe fibrosis/cirrhosis in HCV seroconverters among persons with human immunodeficiency virus (HIV) infection. Methods: We...
3.
Graziano F, Ruzzo A, Giacomini E, Ricciardi T, Aprile G, Loupakis F, et al.
Pharmacogenomics J
. 2016 Mar;
17(3):258-264.
PMID: 26927284
Production of lactate even in the presence of sufficient levels of oxygen (aerobic glycolysis) seems the prevalent energy metabolism pathway in cancer cells. The analysis of altered expression of effectors...
4.
Saracino A, Lorenzini P, Caputo S, Girardi E, Castelli F, Bonfanti P, et al.
Clin Microbiol Infect
. 2015 Nov;
22(3):288.e1-8.
PMID: 26551839
Migrant and Italian HIV-infected patients (n = 5773) enrolled in the ICONA cohort in 2004-2014 were compared for disparities in access to an initial antiretroviral regimen and/or risk of virologic...
5.
Graziano F, Catalano V, Lorenzini P, Giacomini E, Sarti D, Fiorentini G, et al.
Pharmacogenomics J
. 2014 Mar;
14(5):418-23.
PMID: 24663077
In gastric cancer, available clinical studies focusing on the activated hepatocyte growth factor (HGF)/MET pathway are limited to surgical and often heterogeneous series. MET copy number gain (CNG) and an...
6.
Angeletti C, Pezzotti P, Antinori A, Mammone A, Navarra A, Orchi N, et al.
HIV Med
. 2014 Feb;
15(3):165-74.
PMID: 24495188
Objectives: Combination antiretroviral therapy (cART) has become the main driver of total costs of caring for persons living with HIV (PLHIV). The present study estimated the short/medium-term cost trends in...
7.
Lorenzini P, Guardabassi L
Policlinico Prat
. 2010 Mar;
54(5-6):110-23.
PMID: 20334214
No abstract available.
8.
Lorenzini P
Arch Ital Mal Appar Dig
. 2010 Mar;
13(3):159-239.
PMID: 20255387
No abstract available.
9.
Zaccarelli M, Lorenzini P, Tozzi V, Forbici F, Ceccherini-Silberstein F, Gori C, et al.
Infection
. 2009 Mar;
37(3):203-9.
PMID: 19274429
Background: Treatment guidelines for multi-experienced HIV patients have recently evolved from aiming to preserve immunity to achieving virological success, largely due to the availability of new antiretroviral drugs and drug...
10.
Santoro M, Bertoli A, Lorenzini P, Ceccherini-Silberstein F, Gianotti N, Mussini C, et al.
Infection
. 2009 Jan;
37(3):233-43.
PMID: 19169632
Objectives: The protease inhibitor atazanavir (ATV) can be used either boosted by ritonavir (ATV300/r) or unboosted (ATV400). To date, however, genotypic resistance scores (GRSs) have been developed only for boosted-ATV....